A study of IMP321 in cancer patients.
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Eftilagimod alpha (Primary)
- Indications Cancer
- Focus Adverse reactions; Proof of concept
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 17 Dec 2015 New trial record